FDA Approves Sofdra
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Botanix Pharmaceuticals Limited has announced the FDA approval of Sofdra, a new topical gel for treating primary axillary hyperhidrosis, which is excessive underarm sweating. The company plans to launch a patient experience program in the third quarter of the year, with expectations for initial revenue from Sofdra in the fourth quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/fda-approves-sofdra
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Final Sofdra Labelling Discussions with FDA
- March 2024 Quarterly Activities Report and Appendix 4C
- S&P DJI Announces March 2024 Quarterly Rebalance
- Botanix Pharmaceuticals Half Year Report
- December 2023 Quarterly Activities Report and Appendix 4C
Later from Botanix Pharmaceuticals
- Botanix $70 Million Institutional Capital Raising
- June 2024 Quarterly Activities Report and Appendix 4C
- Botanix Appendix 4E & Announcement of Commercial Day Webinar
- September 2024 Quarterly Activities Report and Appendix 4C
- Botanix Pharmaceuticals: Releases Quarterly Reports
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals